<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25100" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Microalbuminuria</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Prasad</surname>
            <given-names>Rohan M.</given-names>
          </name>
          <aff>Michigan State University - Sparrow Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bali</surname>
            <given-names>Atul</given-names>
          </name>
          <aff>University of Virginia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tikaria</surname>
            <given-names>Richa</given-names>
          </name>
          <aff>MSU</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rohan Prasad declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Atul Bali declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Richa Tikaria declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25100.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>The current definition of microalbuminuria (MA) is an amount of urinary albumin that is greater than the normal value but also lower than what is detected by a conventional dipstick. Thus, the rate of urine albumin excretion (UAE) in microalbuminuria is 30 to 300 mg/d. This activity outlines the etiology, diagnosis, and treatment of microalbuminuria. It describes the future possible sequelae of microalbuminuria without intervention. Additionally, it highlights the importance of the interprofessional team&#x02019;s role in screening, managing, and treating this disease and its comorbidities to improve the patient&#x02019;s quality of life.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the pathophysiologic basis of microalbuminuria.</p></list-item><list-item><p>Describe the expected lab findings for a patient with microalbuminuria.</p></list-item><list-item><p>Outline the recommended management strategies for microalbuminuria.</p></list-item><list-item><p>Summarize the need for an interprofessional team approach to caring for a patient with microalbuminuria.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25100&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25100">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25100.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The main functions of albumin are to maintain plasma oncotic pressure via its negatively charged surface and colloidal nature, provide nutrition to renal tubular cells, and serve as an antioxidant. Hepatocytes produce approximately 10-15 g of albumin daily, which is regulated by interstitial colloidal pressure. Albumin exits the blood and is reabsorbed by the lymphatic system at a rate of 4.5% per hour.<xref ref-type="bibr" rid="article-25100.r1">[1]</xref></p>
        <p>There are many barriers to albumin within the glomerular filtration system of the nephron. At physiological pH, the glomerular capillary wall and endothelial cells repel albumin, as they are all negatively charged. The glomerular basement membrane (GBM) is a porous system, but normally these exits are too small to permit the passage of albumin. Additionally, the megalincubulin complex degrades albumin in the nephron, specifically the proximal convoluted tubule. The underlying function is to preserve amino acids for further use but is also another method of restricting the passage of albumin.<xref ref-type="bibr" rid="article-25100.r1">[1]</xref></p>
        <p>Through the dysfunction of the GBM filtration barrier, albumin can be secreted into the urine, and the amount that is present is important.<xref ref-type="bibr" rid="article-25100.r1">[1]</xref> The current definition of microalbuminuria (MA) is an amount of urinary albumin greater than the normal value but also lower than what is detected by a conventional dipstick. Thus, the rate of urine albumin excretion (UAE) in microalbuminuria is 30 to 300 mg/24 hours. In other units, it can also mean&#x000a0;30&#x02013;300 mcg/mg creatinine or 20&#x02013;200 mcg/min on two out of three urine collections. This value is derived from studies that evaluated adults but could also be applied to the pediatric population.<xref ref-type="bibr" rid="article-25100.r2">[2]</xref><xref ref-type="bibr" rid="article-25100.r3">[3]</xref> Macroalbuminuria, on the other hand, is classified as greater than 100 mg/12 hours or 300 mg/24 hours.&#x000a0;The diagnosis of diabetic kidney disease requires a person with type 1 or 2 diabetes to have persistently elevated albuminuria (more than 300 mg/24 hours), diabetic retinopathy, and the absence of other kidney diseases.</p>
        <p>The current diagnosis of microalbuminuria also includes a urinary albumin/creatinine ratio (UACR) ranging between 2&#x000a0;to 20 mg/g. By including creatinine, it corrects the value for urine concentration and volume. However, other factors can affect the level of UACR, including gender, race, blood pressure, time of day, muscle mass, and amount of food, water, and salt intake. Thus, UACR can vary by up to 40% daily. In addition to the individual variability, one should be cautious that some cases have an elevated UACR at&#x000a0;baselines, such as males, African Americans, Asians, smokers, people with higher muscle mass, patients with urinary tract infections, and genital leakage.<xref ref-type="bibr" rid="article-25100.r2">[2]</xref><xref ref-type="bibr" rid="article-25100.r3">[3]</xref><xref ref-type="bibr" rid="article-25100.r4">[4]</xref> Due to the considerable variation, one should obtain three UACR measurements that are each one month apart.<xref ref-type="bibr" rid="article-25100.r5">[5]</xref></p>
      </sec>
      <sec id="article-25100.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Microalbuminuria develops from a dysfunction of the GBM permitting albumin to enter the urine. The enzyme N-deacetylase is necessary to form heparan sulfate, which is how the GBM derives its negative charge. Furthermore, inadequate control of blood sugars inhibits this enzyme, reducing the negative charge on GBM and allowing excessive amounts of albumin to leak out.<xref ref-type="bibr" rid="article-25100.r4">[4]</xref> Advanced glycosylation end-products can also neutralize the negative charge of albumin by binding with the proteins of both the GBM and mesangial matrix.<xref ref-type="bibr" rid="article-25100.r6">[6]</xref> Additionally, hyperglycemia initiates the glycation of GBM and podocyte receptors interfering with the charge on GBM.<xref ref-type="bibr" rid="article-25100.r1">[1]</xref><xref ref-type="bibr" rid="article-25100.r2">[2]</xref><xref ref-type="bibr" rid="article-25100.r6">[6]</xref></p>
        <p>The current hypothesis, known as the &#x02018;Steno hypothesis,&#x02019; is that systemic vascular endothelial dysfunction initiates the development of microalbuminuria and cardiovascular disease, as there is a strong correlation between these three variables.<xref ref-type="bibr" rid="article-25100.r2">[2]</xref><xref ref-type="bibr" rid="article-25100.r3">[3]</xref><xref ref-type="bibr" rid="article-25100.r7">[7]</xref><xref ref-type="bibr" rid="article-25100.r8">[8]</xref> Therefore, having comorbidities that cause endothelial damage is considered a risk factor. These include increased age, insulin resistance, dyslipidemia, obesity, hypertension, decreased physical activity, and smoking.<xref ref-type="bibr" rid="article-25100.r5">[5]</xref> Some studies predict a genetic component linking together microalbuminuria, atherosclerosis, and even nephropathy. An increased UAE rate was seen among patients with a deletion-deletion polymorphism of the ACE gene.<xref ref-type="bibr" rid="article-25100.r6">[6]</xref></p>
      </sec>
      <sec id="article-25100.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>A study evaluating microalbuminuria in 22,244 patients (aged 6&#x000a0;to 80 years) reported a prevalence of 7.8%, especially in those older than 40 years. Women had a higher prevalence of 9.7%, whereas men had 6.1%.<xref ref-type="bibr" rid="article-25100.r2">[2]</xref> Moreover, evidence shows that the prevalence increases with age. Regarding the age groups of 20&#x000a0;to 49, 50&#x000a0;to 69, and more than 70 years, the prevalence of microalbuminuria was 5.8%, 11.4%, and 22.7%.<xref ref-type="bibr" rid="article-25100.r7">[7]</xref></p>
        <p>Microalbuminuria has been associated with patients who have type 1 or type 2 diabetes. For patients with type 1, the prevalence of microalbuminuria within the first three years after diagnosis is only 6%; however, after five years, it is 41%. In type 2, the prevalence is 20 to 25% for newly diagnosed and long-standing diabetics.<xref ref-type="bibr" rid="article-25100.r8">[8]</xref><xref ref-type="bibr" rid="article-25100.r9">[9]</xref> In patients with uncontrolled hypertension, microalbuminuria was seen in 47.4% of patients, whereas, in patients with controlled blood pressure, it was 36.7%.<xref ref-type="bibr" rid="article-25100.r10">[10]</xref></p>
      </sec>
      <sec id="article-25100.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Microalbuminuria arises when GBM, a complex sieve, leaks an increased amount of albumin. The proposed mechanism is a combination of glomerular size enlargement, GBM thickening, mesangial expansion, and podocyte foot process effacement. Microalbuminuria can also occur via inadequate tubular reabsorption.<xref ref-type="bibr" rid="article-25100.r2">[2]</xref><xref ref-type="bibr" rid="article-25100.r7">[7]</xref></p>
        <p>Dysregulated enzymatic metabolism of the extracellular matrix is the pathogenesis behind developing endothelial damage.<xref ref-type="bibr" rid="article-25100.r3">[3]</xref><xref ref-type="bibr" rid="article-25100.r8">[8]</xref> Thus, at vascular places other than just the renal system, the albumin can either leak out of or enter the vessel wall. When this happens, albumin can stimulate inflammation, lipid accumulation, and atherosclerosis, which eventually could form fixed albuminuria and decreased kidney function.<xref ref-type="bibr" rid="article-25100.r7">[7]</xref></p>
      </sec>
      <sec id="article-25100.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>There are structural changes at the level of GBM that lead to microalbuminuria. However, these are heterogeneous and may even be present in patients with normoalbuminuric diabetes. The GBM alterations are typically seen in type 1 diabetes but not type 2.<xref ref-type="bibr" rid="article-25100.r8">[8]</xref></p>
        <p>Furthermore, researchers found no correlation between increased GBM permeability and any histological changes. Since the majority of the GBM dysfunction is through altered charge selectivity, not size, it would not appear on histology.<xref ref-type="bibr" rid="article-25100.r2">[2]</xref><xref ref-type="bibr" rid="article-25100.r8">[8]</xref></p>
      </sec>
      <sec id="article-25100.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>History Taking</bold>
</p>
        <p>Microalbuminuria, in itself, has not been associated with any specific symptoms. However, due to its link with diabetes, obesity, hypertension, and cardiovascular events, providers should focus on history and physical examination to assess for these complications. Specifically, paying attention to any personal or family history of renal, cardiac, and systemic diseases could reveal pertinent information. Additionally, patients with diabetes may present with symptoms of cardiac disease, vision difficulties, and urinary tract disorders. On physical exam, it is particularly important to evaluate for elevated blood pressure, abnormal cardiac exam, carotid pulse for bruits, and lower extremity swelling.<xref ref-type="bibr" rid="article-25100.r11">[11]</xref></p>
        <p>The majority of patients do not have any symptoms, and microalbuminuria is picked up on routine laboratory testing that is carried out to evaluate systemic diseases, such as diabetes mellitus or hypertension, or&#x000a0;when a well-person examination is conducted.<xref ref-type="bibr" rid="article-25100.r12">[12]</xref></p>
        <p>As microalbuminuria occurs&#x000a0;mostly in the absence of any serious underlying renal disease, more benign and common causes of microalbuminuria should be considered first.&#x000a0;The following questions should be asked:</p>
        <list list-type="bullet">
          <list-item>
            <p>Is this transient - This may be&#x000a0;because of&#x000a0;physical exertion and fever</p>
          </list-item>
          <list-item>
            <p>Is this orthostatic - Typically seen in tall, thin adolescents or people younger than 30 years,&#x000a0;there is an association with&#x000a0;severe lordosis; normal renal function and albuminuria are frequently less than 1 g/24 hours<xref ref-type="bibr" rid="article-25100.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Is nonrenal disease causing it, such as severe cardiac failure, sleep apnea - Normal renal function and albumin loss is less than 1 g/24 hours</p>
          </list-item>
          <list-item>
            <p>Are there any symptoms suggestive of nephrotic syndrome or significant glomerular pathology&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Are there any changes in the appearance of urine, such as red/smoky, frothy; is there any correlation of this to a respiratory tract infection</p>
          </list-item>
          <list-item>
            <p>Is there ankle, periorbital, labial, or scrotal edema</p>
          </list-item>
          <list-item>
            <p>Has the patient ever been diagnosed with high blood pressure</p>
          </list-item>
          <list-item>
            <p>Is there a history of high cholesterol levels in the patient's blood</p>
          </list-item>
          <list-item>
            <p>Has the patient ever had a diagnosis of a multisystem disease or another glomerulopathy</p>
          </list-item>
          <list-item>
            <p>Is there a past or family history of any renal disease</p>
          </list-item>
          <list-item>
            <p>If the patient has diabetes mellitus, for how long;&#x000a0;are there any complications, such as retinopathy</p>
          </list-item>
          <list-item>
            <p>Is a family history of&#x000a0;diabetic nephropathy present</p>
          </list-item>
          <list-item>
            <p>Are there any multisystem inflammatory diseases present, such as&#x000a0;systemic lupus erythematosus (SLE) or rheumatoid arthritis</p>
          </list-item>
          <list-item>
            <p>Are there symptoms like&#x000a0;joint discomfort, skin rash, bone pain, fever, weight loss, night sweats, or Raynaud syndrome</p>
          </list-item>
          <list-item>
            <p>Is the patient&#x000a0;on any medication, including herbal remedies</p>
          </list-item>
          <list-item>
            <p>Are there any past medical illnesses, such as jaundice, malaria, tuberculosis, syphilis, or endocarditis</p>
          </list-item>
          <list-item>
            <p>Is the patient at risk of&#x000a0;HIV infection or hepatitis</p>
          </list-item>
        </list>
        <p>
<bold>Physical Examination</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Assessment of intravascular volume status is important - Take erect and supine blood pressure and pulse, examine the jugular venous pulse, and listen to heart sounds</p>
          </list-item>
          <list-item>
            <p>Examine for&#x000a0;extravascular volume status - Look for edema, which may not be present in microalbuminuria; if there is a more significant loss, then weight gain and pleural effusions can be seen</p>
          </list-item>
          <list-item>
            <p>Assess&#x000a0;the patient for&#x000a0;the presence&#x000a0;of systemic&#x000a0;features, such as joint swelling or deformity, retinopathy, rash, signs of chronic liver disease, organomegaly, cardiac murmurs, and lymphadenopathy</p>
          </list-item>
          <list-item>
            <p>Look&#x000a0;for complications of protein loss, such as venous thrombosis, although these may not be seen in microalbuminuria</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25100.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The gold standard diagnostic test for the detection of microalbuminuria is a 24-hour urine collection as it has the lowest variability, but it is labor-intensive.<xref ref-type="bibr" rid="article-25100.r3">[3]</xref><xref ref-type="bibr" rid="article-25100.r4">[4]</xref>&#x000a0;As described above, the UACR corrects urine concentration and volume but can vary due to other factors. The urine spot collection, on the other hand, changes depending on the urine volume.<xref ref-type="bibr" rid="article-25100.r3">[3]</xref><xref ref-type="bibr" rid="article-25100.r5">[5]</xref>&#x000a0;Other alternatives have undergone development, but they have similar sensitivities to the 24-hour collection. These are immunoturbidimetry, immunonephelometry, enzyme-linked immunosorbent assays, immunoassays with latex bodies, radial immunodiffusion, and fluoroimmunoassay.<xref ref-type="bibr" rid="article-25100.r3">[3]</xref><xref ref-type="bibr" rid="article-25100.r4">[4]</xref></p>
        <p>As per the National Kidney Foundation and the European Society of Hypertension, in high-risk patients, screening with a UACR is required to evaluate for&#x000a0;microalbuminuria and&#x000a0;its potential complications. The high-risk patient population consists of the elderly, African Americans, Asians, patients with diabetes, patients with hypertension, and patients with a family history of chronic kidney disease (diagnosed at older than 60 years).<xref ref-type="bibr" rid="article-25100.r1">[1]</xref><xref ref-type="bibr" rid="article-25100.r3">[3]</xref><xref ref-type="bibr" rid="article-25100.r14">[14]</xref> However, screening the general population still requires further evaluation to determine if it is beneficial.<xref ref-type="bibr" rid="article-25100.r14">[14]</xref></p>
        <p>Furthermore, the American Diabetes Association recommends that this screening be repeated every year for type 1 diabetes (if the diagnosis is older than five years ago).&#x000a0;As for patients with type 2 diabetes and diabetic nephropathy, the recommendation is also every year, but it should start following the initial diagnosis.<xref ref-type="bibr" rid="article-25100.r1">[1]</xref></p>
        <p>Laboratory investigations should include a basic metabolic panel (to evaluate for decreased GFR, increased creatinine, and electrolyte imbalances) and a complete white count (for leukocytosis). Other&#x000a0;blood tests to be considered for the assessment of associated conditions are blood sugars, hemoglobin A1c, lipid panel, and troponins. Additionally, ultrasound is an option to look for renal and urinary abnormalities. Renal biopsies are rare because of the procedural side effects, and there are no evidence-based recommendations for indications to acquire one.<xref ref-type="bibr" rid="article-25100.r11">[11]</xref></p>
        <p>Evaluation of&#x000a0;microalbuminuria is carried out in&#x000a0;outpatient clinics unless there is a complication. All patients with impaired renal function or evidence of glomerulopathy should be&#x000a0;seen by a nephrologist. The urine dipstick&#x000a0;can primarily detect albumin. Albuminuria is observed in glomerular proteinuria. Some factors can lead to false-positive results, such as the recent use of iodinated radiocontrast agents, gross hematuria, and alkaline urine. The normal&#x000a0;content of urinary protein is less than 150 mg/day.</p>
        <p>Screening for&#x000a0;microalbuminuria can be carried out by doing early morning spot protein or urinary albumin-to-creatinine ratio. If there is significant proteinuria a 24-hour urine collection must be done. This ratio or spot albumin can also be used&#x000a0;for follow-up. If the ratio increases significantly, it becomes advisable to do the 24-hour urine collection.<xref ref-type="bibr" rid="article-25100.r15">[15]</xref><xref ref-type="bibr" rid="article-25100.r16">[16]</xref><xref ref-type="bibr" rid="article-25100.r17">[17]</xref></p>
        <p>Proteinuria/microalbuminuria can be transient. To determine whether it is transient in nature, the following steps should be taken:</p>
        <list list-type="bullet">
          <list-item>
            <p>Urinalysis&#x000a0;and microscopy on 3 separate occasions</p>
          </list-item>
          <list-item>
            <p>Albumin-to-creatinine ratio in a random spot urine sample</p>
          </list-item>
          <list-item>
            <p>Urinalysis of an early-morning urine sample before any physical activity</p>
          </list-item>
        </list>
        <p>To establish whether it is a case of orthostatic proteinuria, the following should be performed:</p>
        <list list-type="bullet">
          <list-item>
            <p>Urine microscopy</p>
          </list-item>
          <list-item>
            <p>Urine collection on two occasions - Daytime (between 7 am and 11 pm) and overnight (between 11 pm and 7 am)&#x000a0;</p>
          </list-item>
        </list>
        <p>In order to determine the cause of albuminuria as the underlying glomerular disease, the following should be done:</p>
        <list list-type="bullet">
          <list-item>
            <p>Urine microscopy &#x02013;&#x000a0;Presence of dysmorphic red blood cells/casts</p>
          </list-item>
          <list-item>
            <p>24-hour urine collection for the quantification of albumin excretion</p>
          </list-item>
          <list-item>
            <p>Serum creatinine, blood glucose, albumin, and cholesterol</p>
          </list-item>
          <list-item>
            <p>Autoantibody panel - If indicated by the clinical picture, test for antinuclear antibody (ANA), antistreptolysin O titers,&#x000a0;anti-DNA antibodies, antineutrophil cytoplasmic antibodies (ANCA), cryoglobulins, anti-glomerular basement membrane (anti-GBM) antibodies, and complement&#x000a0;levels (C3 and C4)&#x000a0;</p>
          </list-item>
        </list>
        <p>Imaging studies in&#x000a0;albuminuria&#x000a0;may include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Renal ultrasonography &#x02013; To establish glomerular disease as the cause of microalbuminuria, it is imperative to look at the echogenicity and size of the kidneys<xref ref-type="bibr" rid="article-25100.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>Chest X-ray or computed tomography (CT) scan &#x02013; If guided by the clinical picture</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25100.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>If&#x000a0;microalbuminuria is present, aggressive measures should ensue with the ultimate goal of decreasing the risk of cardio-metabolic complications.<xref ref-type="bibr" rid="article-25100.r1">[1]</xref> The first-line treatment is lifestyle modification to control diabetes and hypertension. Although it seems trivial, this can save retinal function, prevent further kidney damage, decrease&#x000a0;the risk of cerebrovascular accidents, and&#x000a0;reduce microvascular complications.<xref ref-type="bibr" rid="article-25100.r5">[5]</xref> For patients with type 2 diabetes with microalbuminuria, reports indicate that a normal protein diet of (0.8 g x kg)/(bodyweight x day) was optimal, not a low protein diet.<xref ref-type="bibr" rid="article-25100.r19">[19]</xref> Interestingly, eating chicken instead of red meat saw a reduction in urinary albumin excretion of 46%, along with decreasing total cholesterol and apolipoprotein B in type 2 diabetic patients with microalbuminuria.<xref ref-type="bibr" rid="article-25100.r11">[11]</xref></p>
        <p>Maintaining an A1c of less than 7% has been shown to decrease the risk of developing not only microalbuminuria but also macroalbuminuria. The evidence shows that rosiglitazone and insulin have the best outcomes and the least side effects.<xref ref-type="bibr" rid="article-25100.r11">[11]</xref> Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), or vasodilatory beta-blockers can reduce blood pressure. Although many providers commonly believe that ACE inhibitors and ARBs are interchangeable in the treatment method, some data do not support the effectiveness of ARBs.<xref ref-type="bibr" rid="article-25100.r5">[5]</xref> These classes of drugs have an effect on reducing proteinuria, separate from their antihypertensive effect.<xref ref-type="bibr" rid="article-25100.r20">[20]</xref> In patients younger than 50 years, the blood pressure goal should be 120/70-75 mm Hg, whereas it is slightly higher at 125-130/80-85 mmHg in those older than 50. Moreover, ACE inhibitors are useful in patients with diabetes, even without hypertension. They have a reno-protective effect of decreasing mesangial expansion and preventing the onset of glomerulosclerosis.<xref ref-type="bibr" rid="article-25100.r6">[6]</xref><xref ref-type="bibr" rid="article-25100.r11">[11]</xref><xref ref-type="bibr" rid="article-25100.r21">[21]</xref> The other anti-hypertensives help manage hypertension but have minimal effect in delaying the progression of kidney disease.<xref ref-type="bibr" rid="article-25100.r3">[3]</xref><xref ref-type="bibr" rid="article-25100.r22">[22]</xref>&#x000a0;Normalization of blood pressure in hypertensive patients results&#x000a0;in a decrease in intraglomerular pressure and albuminuria.<xref ref-type="bibr" rid="article-25100.r23">[23]</xref></p>
        <p>If&#x000a0;treatment with an ARB or ACE inhibitor does not sufficiently control proteinuria in patients with chronic kidney disease, further control of proteinuria can be done by adding mineralocorticoid receptor antagonists (MRA), such as spironolactone or eplerenone. However, MRAs are associated with an increased risk of hyperkalemia. A&#x000a0;new agent, finerenone, which is a nonsteroidal MRA, decreased proteinuria while causing lower rates of hyperkalemia.<xref ref-type="bibr" rid="article-25100.r24">[24]</xref></p>
        <p>Immunosuppressants, such as cyclophosphamide and azathioprine, should be&#x000a0;used in patients who have progressive renal insufficiency or who have vasculitic&#x000a0;changes on renal biopsy.<xref ref-type="bibr" rid="article-25100.r25">[25]</xref></p>
        <p>Several experimental drugs show promising evidence but require further studies to evaluate if they decrease the long-term cardiovascular disease associated with microalbuminuria. For one of the groups, the mechanism is by decreasing protein glycation. These medications are thiamine, ALT-711 (a cross-link breaker of advanced glycation), and pimagedine (a second-generation inhibitor of advanced glycation). Additionally, ruboxistaurin, a protein kinase C-beta inhibitor, has been implicated in decreasing UAE.<xref ref-type="bibr" rid="article-25100.r11">[11]</xref>&#x000a0;Increased vascular endothelial growth factor (VEGF), which regulates vascular permeability and angiogenesis, has been linked with&#x000a0;microalbuminuria in patients with type 2 diabetes. Thus, VEGF inhibitors could be helpful in patients with microalbuminuria.<xref ref-type="bibr" rid="article-25100.r8">[8]</xref> Glycosaminoglycans, such as sulodexide, can also decrease albuminuria.<xref ref-type="bibr" rid="article-25100.r3">[3]</xref> Statins, on the other hand, have a well-documented effect in reducing the risk of cardiovascular disease, but their role in decreasing urinary albumin excretion is still controversial. Due to its cardioprotection, it merits inclusion in the treatment regimen.<xref ref-type="bibr" rid="article-25100.r3">[3]</xref></p>
        <p>When considering the associated comorbidities with microalbuminuria, the treatment recommendations should also include weight loss, aspirin, and maintaining low-density lipoprotein cholesterol of less than 100.<xref ref-type="bibr" rid="article-25100.r11">[11]</xref> Finally, the level of&#x000a0;microalbuminuria can serve as an indicator of treatment response, especially in patients with hyperinsulinemia, insulin resistance, and hypertension.<xref ref-type="bibr" rid="article-25100.r1">[1]</xref><xref ref-type="bibr" rid="article-25100.r3">[3]</xref></p>
        <p>In terms of specific treatments,&#x000a0;sodium-glucose co-transporter 2 (SGLT2) inhibitors, such as canagliflozin and empagliflozin, have gained&#x000a0;popularity not only&#x000a0;in the management of diabetes mellitus but also in reducing the development or further worsening of albuminuria.<xref ref-type="bibr" rid="article-25100.r26">[26]</xref>&#x000a0;A meta-analysis&#x000a0;observed that combination therapy with SGLT2 inhibitors and other hypoglycemic agents helps reduce albuminuria.<xref ref-type="bibr" rid="article-25100.r27">[27]</xref></p>
        <p>Non-dihydropyridine calcium channel blockers (NDCCBs), such as diltiazem and verapamil, decrease proteinuria&#x000a0;more than dihydropyridine calcium channel blockers (DCCBs)&#x000a0;because NDCCBs affect both the afferent and efferent arteriole.<xref ref-type="bibr" rid="article-25100.r28">[28]</xref><xref ref-type="bibr" rid="article-25100.r29">[29]</xref></p>
        <p>Endothelin activation has an association with renal inflammation and fibrosis. Endothelin A (ETA) receptor blockade leads to the dilation of the glomerular capillaries, reducing albumin permeability. Endothelin B (ETB) reduces&#x000a0;arterial pressure by decreasing salt and water reabsorption from the kidneys. Experimental ETA-selective antagonists, such as avosentan and atrasentan,&#x000a0;have been&#x000a0;shown to&#x000a0;decrease proteinuria.<xref ref-type="bibr" rid="article-25100.r30">[30]</xref><xref ref-type="bibr" rid="article-25100.r31">[31]</xref></p>
      </sec>
      <sec id="article-25100.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Microalbuminuria can present in various diseases, kidney-related and non-kidney related.<xref ref-type="bibr" rid="article-25100.r6">[6]</xref> Notably, it has been proposed to be an acute phase reactant and subsequently increases during inflammation, especially ischemia, reperfusion, burns, trauma, sepsis, and surgery. Organ-specific inflammatory conditions that have correlations with&#x000a0;microalbuminuria are periodontitis, obstructive respiratory disease, hepatitis, bowel disease, pancreatitis, rheumatoid arthritis, and psoriasis.<xref ref-type="bibr" rid="article-25100.r4">[4]</xref><xref ref-type="bibr" rid="article-25100.r5">[5]</xref><xref ref-type="bibr" rid="article-25100.r7">[7]</xref>&#x000a0;Furthermore, increased toll-like receptor 4&#x000a0;is found to be associated with microalbuminuria and diabetic kidney disease. Thus, the hypothesis is that inflammation activates further disease progression.<xref ref-type="bibr" rid="article-25100.r32">[32]</xref></p>
        <p>Moreover,&#x000a0;microalbuminuria coinciding with third-trimester pregnancies could indicate the future sequelae of pre-eclampsia.<xref ref-type="bibr" rid="article-25100.r4">[4]</xref></p>
      </sec>
      <sec id="article-25100.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The main reason to test the UAE level is to evaluate the patient for possible future complications. However, providers should not merely view microalbuminuria as a kidney damage marker but as a predictor of kidney dysfunction progression rate and reflect the effect of systemic disorders on the kidney.<xref ref-type="bibr" rid="article-25100.r1">[1]</xref></p>
        <p>It is well known that the glomerular filtration rate (GFR) is useful in staging chronic kidney disease. In comparison to microalbuminuria, GFR is a pure kidney damage marker. Several studies have demonstrated that there is a continuous correlation between&#x000a0;microalbuminuria and developing end-stage renal disease. Therefore, when presented with a patient with a reduced GFR classified under stage 3 or 4, the patient with&#x000a0;microalbuminuria should be considered very high risk instead of high risk as per the GFR. This classification ensures&#x000a0;that prompt action is taken&#x000a0;to prevent further complications, such as macroalbuminuria, diabetic kidney disease, proteinuria, and chronic kidney disease.<xref ref-type="bibr" rid="article-25100.r5">[5]</xref></p>
        <p>Microalbuminuria has links with a high rate of atherosclerotic cardiovascular events (such as coronary artery disease, stroke, and peripheral vascular disease) and subsequently increased morbidity and mortality. The evidence reveals in adults, it is a four to six-fold increase, whereas, in patients with diabetes, it is only two-fold.<xref ref-type="bibr" rid="article-25100.r3">[3]</xref><xref ref-type="bibr" rid="article-25100.r5">[5]</xref><xref ref-type="bibr" rid="article-25100.r6">[6]</xref><xref ref-type="bibr" rid="article-25100.r9">[9]</xref>&#x000a0;The risk of cardiovascular events is even higher for patients with macroalbuminuria versus microalbuminuria. Thus, screening and compliance with the treatment of microalbuminuria could prevent macroalbuminuria and even death.<xref ref-type="bibr" rid="article-25100.r3">[3]</xref><xref ref-type="bibr" rid="article-25100.r6">[6]</xref>&#x000a0;The UACR range for microalbuminuria starts at 2 mg/day, but data shows that the risk between increased UAE and cardiovascular disease can begin even at 1 mg/day.<xref ref-type="bibr" rid="article-25100.r3">[3]</xref></p>
        <p>Among patients with essential hypertension,&#x000a0;microalbuminuria can predict kidney function decline, coronary artery stenosis, and hypertensive retinopathy. Importantly, the latter two are reversible with adequate treatment.<xref ref-type="bibr" rid="article-25100.r5">[5]</xref></p>
      </sec>
      <sec id="article-25100.s12" sec-type="Complications">
        <title>Complications</title>
        <p>With progressive disease, patients can develop macroalbuminuria, diabetic kidney disease, and proteinuria.<xref ref-type="bibr" rid="article-25100.r1">[1]</xref>&#x000a0;The level of serum albumin is unable to predict the nutritional status of a patient. However, during states of extreme starvation, serum albumin is low, and urine albumin is high.</p>
        <p>Other complications&#x000a0;of proteinuria are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pulmonary edema, which is attributable to fluid overload</p>
          </list-item>
          <list-item>
            <p>Acute kidney injury&#x000a0;secondary&#x000a0;to intravascular depletion and progression of kidney disease</p>
          </list-item>
          <list-item>
            <p>Increased risk of cardiovascular diseases</p>
          </list-item>
          <list-item>
            <p>Increased risk of&#x000a0;vascular thromboses,&#x000a0;such as renal vein thrombosis</p>
          </list-item>
          <list-item>
            <p>Increased risk of bacterial infections</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25100.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Due to the possible complications with microalbuminuria, when it is present in labs, one should order further laboratory workup to evaluate the cardiac, renal, and systemic systems. If these values are also concerning, one should consider consulting nephrology or cardiology. When the&#x000a0;provider diagnoses type 2 diabetes, they should refer the patient to nephrologists and ophthalmologists.</p>
      </sec>
      <sec id="article-25100.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The evaluation and treatment of&#x000a0;microalbuminuria require the involvement of the patient. They should understand the importance of compliance with follow-up visits, screening guidelines, lifestyle modifications, and medication regimens. If a collection of 24 hours of urine is advised,&#x000a0;the process should be clearly stated to the patient&#x000a0;with clear written instructions.<xref ref-type="bibr" rid="article-25100.r33">[33]</xref>&#x000a0;All patients should be given information about the possible adverse effects of ARBs and ACE inhibitors, such as angioedema, cough, dizziness, syncope, hyperkalemia, hypotension, and a&#x000a0;nominally increased risk of lung carcinoma.<xref ref-type="bibr" rid="article-25100.r34">[34]</xref></p>
      </sec>
      <sec id="article-25100.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Along with patient education, physicians must understand the drastic implications of microalbuminuria. Strongly advising their patients to be compliant with the recommendations has been shown to prevent future complications, decrease morbidity and mortality, and improve quality of life. Early detection of microalbuminuria has been studied greatly and has been observed to help in halting the progression of the underlying disease. An interprofessional team is crucial in the early screening and management of microalbuminuria. Primary care providers working closely with the patients in the community can ensure early detection of microalbuminuria. With early detection, dietary modification, and treatment ensue earlier, leading to better patient outcomes.</p>
      </sec>
      <sec id="article-25100.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25100&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25100">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/kidney-health/microalbuminuria/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25100">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25100/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25100">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25100.s17">
        <title>References</title>
        <ref id="article-25100.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waghmare</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Goswami</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Microalbuminuria: A Mere Marker or An Ominous Sign?</article-title>
            <source>J Assoc Physicians India</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>64</volume>
            <issue>3</issue>
            <fpage>61</fpage>
            <page-range>61-65</page-range>
            <pub-id pub-id-type="pmid">27731559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Satchell</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Microalbuminuria: causes and implications.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>26</volume>
            <issue>11</issue>
            <fpage>1957</fpage>
            <page-range>1957-65</page-range>
            <pub-id pub-id-type="pmid">21301888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jarraya</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lakhdar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kammoun</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mahfoudh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Drissa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kammoun</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hachicha</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Microalbuminuria: a useful marker of cardiovascular disease.</article-title>
            <source>Iran J Kidney Dis</source>
            <year>2013</year>
            <month>May</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>178</fpage>
            <page-range>178-86</page-range>
            <pub-id pub-id-type="pmid">23689147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lydakis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GY</given-names>
              </name>
            </person-group>
            <article-title>Microalbuminuria and cardiovascular risk.</article-title>
            <source>QJM</source>
            <year>1998</year>
            <month>Jun</month>
            <volume>91</volume>
            <issue>6</issue>
            <fpage>381</fpage>
            <page-range>381-91</page-range>
            <pub-id pub-id-type="pmid">9709456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khosla</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sarafidis</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Microalbuminuria.</article-title>
            <source>Clin Lab Med</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>635</fpage>
            <page-range>635-53, vi-vii</page-range>
            <pub-id pub-id-type="pmid">16938588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakris</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Microalbuminuria: prognostic implications.</article-title>
            <source>Curr Opin Nephrol Hypertens</source>
            <year>1996</year>
            <month>May</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>219</fpage>
            <page-range>219-23</page-range>
            <pub-id pub-id-type="pmid">8737856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdelhafiz</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>El Nahas</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Microalbuminuria: marker or maker of cardiovascular disease.</article-title>
            <source>Nephron Exp Nephrol</source>
            <year>2011</year>
            <volume>119 Suppl 1</volume>
            <fpage>e6</fpage>
            <page-range>e6-10</page-range>
            <pub-id pub-id-type="pmid">21832857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Satchell</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Tooke</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?</article-title>
            <source>Diabetologia</source>
            <year>2008</year>
            <month>May</month>
            <volume>51</volume>
            <issue>5</issue>
            <fpage>714</fpage>
            <page-range>714-25</page-range>
            <pub-id pub-id-type="pmid">18347777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheth</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Diabetes, microalbuminuria and hypertension.</article-title>
            <source>Clin Exp Hypertens</source>
            <year>1999</year>
            <season>Jan-Feb</season>
            <volume>21</volume>
            <issue>1-2</issue>
            <fpage>61</fpage>
            <page-range>61-8</page-range>
            <pub-id pub-id-type="pmid">10052642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fici</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bakir</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Beyaz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Makel</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Robles</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>PAIT-survey-Prevalence of albuminuria in patients with diabetes and hypertension in Turkey.</article-title>
            <source>Prim Care Diabetes</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>558</fpage>
            <page-range>558-564</page-range>
            <pub-id pub-id-type="pmid">30327190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gross</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>de Azevedo</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Silveiro</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Canani</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Caramori</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Zelmanovitz</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Diabetic nephropathy: diagnosis, prevention, and treatment.</article-title>
            <source>Diabetes Care</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>164</fpage>
            <page-range>164-76</page-range>
            <pub-id pub-id-type="pmid">15616252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cho</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of microalbuminuria and its associated cardiometabolic risk factors in Korean youth: Data from the Korea National Health and Nutrition Examination Survey.</article-title>
            <source>PLoS One</source>
            <year>2017</year>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>e0178716</fpage>
            <pub-id pub-id-type="pmid">28575100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanaka</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Orthostatic proteinuria revisited: new clinical impact of the "old" clinical entity?</article-title>
            <source>Ann Transl Med</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>13</issue>
            <fpage>814</fpage>
            <pub-id pub-id-type="pmid">32793659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Hung</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Chien</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Microalbuminuria screening for detecting chronic kidney disease in the general population: a systematic review.</article-title>
            <source>Ren Fail</source>
            <year>2013</year>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>607</fpage>
            <page-range>607-14</page-range>
            <pub-id pub-id-type="pmid">23534678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naderi</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Reilly</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Primary care approach to proteinuria.</article-title>
            <source>J Am Board Fam Med</source>
            <year>2008</year>
            <season>Nov-Dec</season>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>569</fpage>
            <page-range>569-74</page-range>
            <pub-id pub-id-type="pmid">18988725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ix</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Wassel</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Froissart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Navis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rodby</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Levey</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Equations to estimate creatinine excretion rate: the CKD epidemiology collaboration.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>184</fpage>
            <page-range>184-91</page-range>
            <pub-id pub-id-type="pmid">20966119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viswanathan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Upadhyay</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Assessment of proteinuria.</article-title>
            <source>Adv Chronic Kidney Dis</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>243</fpage>
            <page-range>243-8</page-range>
            <pub-id pub-id-type="pmid">21782130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spatola</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Andrulli</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Doppler ultrasound in kidney diseases: a key parameter in clinical long-term follow-up.</article-title>
            <source>J Ultrasound</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>243</fpage>
            <page-range>243-250</page-range>
            <pub-id pub-id-type="pmid">27965714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Narita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Koshimura</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meguro</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kitazato</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Determination of optimal protein contents for a protein restriction diet in type 2 diabetic patients with microalbuminuria.</article-title>
            <source>Tohoku J Exp Med</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>193</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-55</page-range>
            <pub-id pub-id-type="pmid">11321050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Hunsicker</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Rohde</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.</article-title>
            <source>N Engl J Med</source>
            <year>1993</year>
            <month>Nov</month>
            <day>11</day>
            <volume>329</volume>
            <issue>20</issue>
            <fpage>1456</fpage>
            <page-range>1456-62</page-range>
            <pub-id pub-id-type="pmid">8413456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chatzikyrkou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Menne</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Izzo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Viberti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rabelink</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ruilope</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Rump</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mertens</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Haller</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Predictors for the development of microalbuminuria and interaction with renal function.</article-title>
            <source>J Hypertens</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>12</issue>
            <fpage>2501</fpage>
            <page-range>2501-2509</page-range>
            <pub-id pub-id-type="pmid">29035939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deferrari</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Repetto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Calvi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ciabattoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Robaudo</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Diabetic nephropathy: from micro- to macroalbuminuria.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>1998</year>
            <volume>13 Suppl 8</volume>
            <fpage>11</fpage>
            <page-range>11-5</page-range>
            <pub-id pub-id-type="pmid">9870419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roozbeh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Banihashemi</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ghezlou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Afshariani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Salari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sagheb</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy.</article-title>
            <source>Ren Fail</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>172</fpage>
            <page-range>172-8</page-range>
            <pub-id pub-id-type="pmid">20199178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakris</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Gansevoort</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Haller</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Remuzzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rossing</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schmieder</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Nowack</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kolkhof</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pieper</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kimmeskamp-Kirschbaum</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ruilope</surname>
                <given-names>LM</given-names>
              </name>
              <collab>Mineralocorticoid Receptor Antagonist Tolerability Study&#x02013;Diabetic Nephropathy (ARTS-DN) Study Group</collab>
            </person-group>
            <article-title>Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2015</year>
            <month>Sep</month>
            <day>01</day>
            <volume>314</volume>
            <issue>9</issue>
            <fpage>884</fpage>
            <page-range>884-94</page-range>
            <pub-id pub-id-type="pmid">26325557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pozzi</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Treatment of IgA nephropathy.</article-title>
            <source>J Nephrol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-5</page-range>
            <pub-id pub-id-type="pmid">26577268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davidson</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence.</article-title>
            <source>Postgrad Med</source>
            <year>2019</year>
            <month>May</month>
            <volume>131</volume>
            <issue>4</issue>
            <fpage>251</fpage>
            <page-range>251-260</page-range>
            <pub-id pub-id-type="pmid">30929540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Nie</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bao</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.</article-title>
            <source>Int Urol Nephrol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>655</fpage>
            <page-range>655-669</page-range>
            <pub-id pub-id-type="pmid">30830656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carmines</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Navar</surname>
                <given-names>LG</given-names>
              </name>
            </person-group>
            <article-title>Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II.</article-title>
            <source>Am J Physiol</source>
            <year>1989</year>
            <month>Jun</month>
            <volume>256</volume>
            <issue>6 Pt 2</issue>
            <fpage>F1015</fpage>
            <page-range>F1015-20</page-range>
            <pub-id pub-id-type="pmid">2544103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Toto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy.</article-title>
            <source>Kidney Int</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>54</volume>
            <issue>3</issue>
            <fpage>889</fpage>
            <page-range>889-96</page-range>
            <pub-id pub-id-type="pmid">9734613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kohan</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Pollock</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>76</volume>
            <issue>4</issue>
            <fpage>573</fpage>
            <page-range>573-9</page-range>
            <pub-id pub-id-type="pmid">23228194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wenzel</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Littke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kuranoff</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>J&#x000fc;rgens</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bruck</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ritz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Philipp</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>A</given-names>
              </name>
              <collab>SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study Investigators</collab>
            </person-group>
            <article-title>Avosentan reduces albumin excretion in diabetics with macroalbuminuria.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>655</fpage>
            <page-range>655-64</page-range>
            <pub-id pub-id-type="pmid">19144760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verzola</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cappuccino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>D'Amato</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Villaggio</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gianiorio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mij</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simonato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Viazzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Salvidio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Garibotto</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria.</article-title>
            <source>Kidney Int</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>86</volume>
            <issue>6</issue>
            <fpage>1229</fpage>
            <page-range>1229-43</page-range>
            <pub-id pub-id-type="pmid">24786705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Snyder</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Workup for proteinuria.</article-title>
            <source>Prim Care</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>719</fpage>
            <page-range>719-35</page-range>
            <pub-id pub-id-type="pmid">25439530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25100.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Athavale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Management of proteinuria: blockade of the renin-angiotensin-aldosterone system.</article-title>
            <source>Aust Prescr</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>121</fpage>
            <page-range>121-125</page-range>
            <pub-id pub-id-type="pmid">32921887</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
